In the news:
Stocks making the biggest moves midday: Nuvalent, Alcoa, Sprouts Farmers Market, Apple and more
Nuvalent
Save
ShareKey facts
- city: Cambridge
- state: MA
- country: United States
- sector: Health Care
- industry: Biotechnology
- CEO: Dr. James R. Porter Ph.D.
Classified as: organization
Summary
Nuvalent is a company. It is located in Cambridge, the United States. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business see more
Nuvalent is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 293.8M $
- Debt: 0.00 $
- Employees: 48 people
- Free cash flow: -26512400 $
- Market cap: 828.6M $
- Revenues:
get
Premium to see estimate
Stocks from Nuvalent
Talking Points:
- Precisely targeted therapies for patients with cancer
- With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
- Creating #preciselytargetedtherapies for patients with cancer, designed to overcome limitations of existing therapies for clinically proven kinase targets
- 11-50 employees Headquarters Cambridge, Massachusetts Type Privately Held Founded 2017 Locations Primary One Broadway 14th Floor Cambridge, Massachusetts 02142, US Get directions Employees at...
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Learn more about talking points